Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy

Rezafungin is a novel echinocandin currently in phase 2 studies, differentiated by a long half-life that allows once-weekly dosing and a safety profile that allows higher doses. Several potential areas of use for rezafungin were identified.